Floatz logo

Cyclophosphamide

Cutaneous Neoplasm

Obsidian Therapeutics, Inc.Small moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Cutaneous Neoplasm cohort.

Asset / SponsorPhaseRating
Epirubicin
Memorial Sloan Kettering Cancer Center
Phase 1CC
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 1CC
mq719
Memorial Sloan Kettering Cancer Center
Phase 1CC

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →